In a nutshell This study summarised the side effects of ibrutinib (Imbruvica) and how to manage them. Some background Ibrutinib is an FDA approved drug used to treat lymphoma and leukemia. It works on the immune cells in the body which may lead to many side effects. These include diarrhea, upper respiratory infections, bleeding, tiredness,...
Read MoreTreatment(s) already received-Biological therapy Posts on Medivizor
Searching for patients with advanced non-small cell lung cancer to test a new T-cell treatment
In a nutshell This phase 2 trial will investigate the effectiveness of genetically-engineered cell treatment (GECT) in advanced cancer. The main outcome will be the response to treatment. This trial is recruiting at the National Cancer Institute, Maryland, US. The details There are limited treatment options for advanced cancer. One...
Read MoreLooking for patients with non-small cell lung cancer to test a new immunotherapy combination
In a nutshell This phase 2 trial will investigate the safety and effectiveness of different treatment combinations containing durvalumab (Imfinzi) in non-small cell lung cancer (NSCLC). The main outcome will be the objective response rate (ORR). The details Non-small cell lung cancer (NSCLC) is a common form of lung cancer. It is often diagnosed at...
Read MoreLooking for patients advanced colorectal cancer to test a new treatment and a predictive blood test
In a nutshell This trial is examining the effectiveness of circulating cell-free tumor DNA (cCFTD) as a predictive factor for the treatment of advanced colorectal cancer with regorafenib (Stivarga) or TAS-102. The main outcome to be measured will be to evaluate the ability of early change of cCFTD after the start of the treatment. This trial will be...
Read MoreEffectiveness of venetoclax in patients with unresponsive chronic lymphocytic leukemia
In a nutshell This study looked at the effectiveness of venetoclax (Venclexta) in the treatment of relapsed or unresponsive chronic lymphocytic leukemia (CLL). Researchers found venetoclax improved outcomes in these patients. Some background CLL is a cancer of the bone marrow. This may lead to an abnormal immune system. It is also often...
Read MoreSearching for patients with advanced breast cancer to trial a new medication
In a nutshell This trial is aiming to determine how effective a new medication called elacestrant is for treating advanced breast cancer. The main outcome that will be measured is how long the patients go without the disease progressing. This study is being conducted in Illinois, United States. The details Some breast cancers grow in response to the...
Read MoreRe-treatment with cetuximab improves cancer outcomes in patients with inoperable colorectal cancer
In a nutshell This study investigated the effect of cetuximab (Erbitux) in patients with metastatic (spread to other parts of the body) colorectal cancer who did not respond to initial cetuximab treatment. Researchers suggested that this treatment may be beneficial in longer treatment durations. Some background The standard treatment for patients...
Read MoreIs blood cell transplant effective in HIV-associated lymphoma?
In a nutshell This study investigated the effects of blood cell transfer in patients with human immunodeficiency virus (HIV) who had developed lymphomas. At 4 years, it was found that 70% of patients survived following blood cell transfer. Some background Lymphomas are forms of cancer which affect the blood cells. Two common types of lymphoma are...
Read MoreComparing targeted therapy to chemotherapy for patients with advanced NSCLC
In a nutshell This trial compared the effectiveness of alectinib (Alecensa) against chemotherapy for treating patients with ALK-positive non-small-cell lung cancer that have progressed passed previous targeted therapy. The authors determined that alectinib was more effective than chemotherapy at treating this subgroup of patients. Some background Lung...
Read MoreBosutinib as second line treatment for chronic myeloid leukemia
In a nutshell This study aimed to investigate the effectiveness and safety of bosutinib as a second line therapy for patients with chronic phase chronic myeloid leukemia (CML). This study concluded that bosutinib was effective and safe for these patients as a second line therapy. Some background Bosutinib (bosulif) is a tyrosine kinase inhibitor (TKI...
Read MoreLooking for patients with HER2-positive inoperable breast cancer to examine the efficacy and safety of antibody-drug conjugate SYD985
In a nutshell This trial is examining the effectiveness of the antibody-drug conjugate SYD985 for HER2-positive inoperable advanced breast cancer. The main outcome to be measured will be time from treatment until disease progression or the time taken for tumor growth or spread. This study is being conducted in Baltimore, Maryland, inthe United...
Read MoreInhibitor Therapies: How Do They Treat CLL?
Video information: Treatments that inhibit CLL, such as BTK Inhibitors, are becoming more commonly used in patients. So, how do they work? CLL expert Dr. John Burke explains the mechanism of action that inhibitor therapies use to treat CLL. Dr. Burke also discusses how inhibitors affect cancer proteins and how they differ from...
Read More
